HOME >> MEDICINE >> NEWS
Two years after gene therapy treatments, severe angina patients showed prolonged clinical benefit

ss III or IV angina refractory to medical therapy who also had multivessel occlusive coronary artery disease not amenable to revascularization. Patients were treated in dose-escalating fashion at 200, 800 or 2,000 mg dose, injected directly into the heart muscle with a hypodermic needle after a mini-thoracotomy, a surgical incision in the chest wall.

Patients were followed for clinical events after one year by hospital records, follow-up visits or telephone contact. At the most recent follow-up, no patients had Class IV angina, and only three (11.5%) had Class II angina, while the remaining had Class I or II angina. Compared to baseline, average angina class decreased from 3.6 0.5 to 1.3 1.0 after the first year. This benefit persisted to 24 months when the mean angina class was 1.5 1.2 (p< 0.05).

Major clinical events such as death, myocardial infarction (MI, or heart attack) and repeat revascularization were uncommon during the first year but more frequent after one year at a rate consistent with the severity of the underlying disease in a population with advanced atherosclerosis. The majority of events were the result of progression of disease in areas of the heart remote from the site of injection.

Previous Clinical Data

Physicians who participated in the Phase I study published previous reports stating that the results demonstrated the safety of VEGF-2 and citing significant improvement in the exercise tolerance time in all dose groups. The study reports reflected that 80% of the patients treated experienced an improvement (decrease) in angina class of two or more levels and 40% of the patients experienced complete elimination of angina symptoms. Similarly, significant reductions in the number of angina episodes per week and the number of nitroglycerin tablets taken were observed. Given the invasive nature of this trial, there was not a control group that received a placebo.

The Phase I trial was followe
'"/>

Contact: Justin Jackson
jjackson@burnsmc.com
212-213-0006
Burns McClellan
8-Mar-2005


Page: 1 2 3 4 5

Related medicine news :

1. Many children are undervaccinated or have delayed vaccinations in their first 2 years of life
2. 14-year study finds that quitting smoking adds years to life
3. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
4. Cumulative trauma in adulthood can worsen health in later years
5. Malnutrition in early years leads to low IQ and later antisocial behavior, USC study finds
6. Vioxx should have been withdrawn 4 years ago
7. Cancer burden seen even many years after diagnosis
8. Scientists meet to review Envisat results after two and a half years of operations
9. Study finds lung transplants increase survival of cystic fibrosis patients by more than four years
10. Full recovery after cell transplantation for treating leukemia or lymphoma can take 3-5 years
11. Full recovery after cell transplantation for treating leukemia or lymphoma can take 3-5 years

Post Your Comments:
(Date:10/22/2014)... Va. (PRWEB) October 22, 2014 ... Innovation , which is dedicated to distribute health ... of healthcare delivery worldwide announced the development of ... which patients expect when receiving healthcare. These are ... for patient-centered care: “providing care that is respectful ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most ... recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the ... the world. , “iPower is one of the most ... various kinds of useful products for new and old ... customer service and a number of features which will ...
(Date:10/22/2014)... CA (PRWEB) October 22, 2014 Lintelus, ... Cormier, Sr. Vice President of Sales, will be speaking ... upcoming Meetings Technology Expo on October 28, at the ... be hosting a booth as well as a Tech ... Lintelus Meeting can create a more engaging event experience. ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter , ... in vitro fertilization (IVF) are only about half as likely ... reproduction technique, new research indicates, and the racial disparity persists ... about 31 percent of white patients became pregnant after IVF, ... more than 4,000 IVF cycles over two years to tease ...
(Date:10/22/2014)... News) -- Measures taken by Firestone officials at the ... have limited the spread of the disease there and ... Natural Rubber Co. provides health services to about 80,000 ... populated communities. Between Aug. 1 and Sept. 23, ... those 80,000 people. That incidence rate of 0.09 percent ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
(Date:10/22/2014)... Oct. 22, 2014 Provectus Biopharmaceuticals, Inc. (NYSEMKT: ... its novel investigational drug for cancer, is designed for ... side effects. Its oncology focus is on melanoma, breast ... phase 2 trials of PV-10 as a therapy for ... for atopic dermatitis and psoriasis. This ...
(Date:10/22/2014)... NORWALK, Conn. , Oct. 22, 2014  Recently ... (GERD) have bolstered the already substantial database of evidence. ... and adoption of Stretta therapy for sufferers ... of clinical evidence supporting Stretta therapy as ... coverage policies that make Stretta therapy available to nearly ...
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014   ... and WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... comprehensive genomic profiling to biopharmaceutical companies conducting clinical trials ... Under the terms of the collaboration, Foundation Medicine will ... of Foundation Medicine,s FoundationOne® assay at the WuXi Genome ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5
Cached News: